Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TENX | 8-K | neutral | 5/10 | Tenax Therapeutics presented a comprehensive update on its Phase 3 LEVEL trial of oral levosimendan (TNX-103) in PH-HFpE | Sep 9, 2026 |
| ADAG | 6-K | neutral | 3/10 | Adagene announced a $2.0M milestone payment from Exelixis for a preclinical milestone on XB404, a SAFEbody ADC candidate | Sep 9, 2026 |
| RADX | 6-K | bullish | 7/10 | Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 in pancreatic ductal adenocarcinoma (PDAC), de | Sep 9, 2026 |
| PRQR | 6-K | neutral | 4/10 | ProQR announced the first participant dosed in the Phase 1 study of AX-0811, a next-generation RNA editing oligonucleoti | Sep 9, 2026 |
| COCP | 8-K | neutral | 4/10 | Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139) | Sep 9, 2026 |
| CRDL | 6-K | neutral | 2/10 | Cardiol Therapeutics announced participation in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Con | Sep 9, 2026 |
| TTRX | 8-K | bullish | 5/10 | Turn Therapeutics appointed former CDC Director Dr. Robert R. Redfield as Chief Scientific Officer. This is a high-profi | Sep 9, 2026 |
| BIAF | 8-K | bullish | 6/10 | bioAffinity Technologies (BIAF) announced it has regained compliance with Nasdaq's minimum bid price rule (Listing Rule | Sep 9, 2026 |
| TRIB | 6-K | neutral | 5/10 | Trinity Biotech's Trinovium subsidiary signed a contract with Red Team Investments to supply advanced liquid cooling flu | Sep 9, 2026 |
| XERS | 8-K | bullish | 6/10 | Xeris Biopharma hosted a program overview webinar detailing its comprehensive development plan for XP-8121, an investiga | Sep 9, 2026 |
| MTVA | 8-K | neutral | 4/10 | MetaVia Inc. announced preclinical tissue distribution study results for its obesity drug candidate DA-1726, showing hig | Sep 9, 2026 |
| DARE | 8-K | neutral | 2/10 | Dare Bioscience filed an 8-K on September 9, 2026, to furnish a corporate investor presentation (Exhibit 99.1) under Ite | Sep 9, 2026 |
| GOSS | 8-K | neutral | 3/10 | Gossamer Bio announced a 1-for-80 reverse stock split effective September 10, 2026, to regain compliance with Nasdaq's m | Sep 9, 2026 |
| IMUX | 8-K | neutral | 3/10 | Immunic, Inc. filed an 8-K announcing a Relapsing Multiple Sclerosis (RMS) Research and Development Day webinar held on | Sep 9, 2026 |
| HELP | 6-K | neutral | 2/10 | Helus Pharma (Cybin Inc., Nasdaq: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the H | Sep 9, 2026 |
| CATX | CLUSTER | neutral | 3/10 | Two 10% owner entities of Perspective Therapeutics (Lantheus Holdings, Inc. and Lantheus Alpha Therapy, LLC) sold a comb | Sep 8, 2026 |
| CYTK | CLUSTER | neutral | 3/10 | Two insiders at Cytokinetics sold a combined $622K in open-market transactions over a week. Director Parshall sold $357K | Sep 8, 2026 |
| EIKN | INSIDER-BUY | bullish | 5/10 | A 10% owner, Column Group IV GP, LP, purchased $1.03M worth of EIKN shares on the open market at $11.56 per share on Sep | Sep 8, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt and EVP Paul Mahon executed a cluster of open-market sales totaling ~$6.5M on September 3, 2026, w | Sep 8, 2026 |
| INBX | CLUSTER | bullish | 6/10 | CEO Mark Lappe made a series of open-market purchases totaling ~$2.6M on September 8, 2026, and Director Douglas Forsyth | Sep 8, 2026 |
| MAZE | CLUSTER | bearish | 4/10 | Four top insiders at Maze Therapeutics, CEO, President/R&D/CMO, GC, and CSBO, collectively sold ~$601K in open-market sa | Sep 8, 2026 |
| DYN | CLUSTER | neutral | 3/10 | CEO John Cox and CMO Douglas Kerr sold a total of $131K in DYN shares on September 8, 2026, all at $18.88. The sales are | Sep 8, 2026 |
| INBX | INSIDER-BUY | bullish | 6/10 | CEO Mark Lappe purchased $2.65M of INBX stock across six open-market trades between September 1-8, 2026, at prices rangi | Sep 8, 2026 |
| AMGN | ANALYST-DOWNGRADE | bearish | 4/10 | BMO Capital double downgrade: Outperform → Market Perform | Sep 8, 2026 |
| MAZE | CLUSTER | neutral | 2/10 | Four top Maze Therapeutics insiders, CEO, President/R&D/CMO, GC, and CSBO, sold a combined ~$498K in open-market shares | Sep 5, 2026 |
| ARTV | CLUSTER | neutral | 2/10 | Two C-suite insiders at Artiva Biotherapeutics (COO/CLO and CMO) sold a combined $192K in open-market sales over a 7-day | Sep 5, 2026 |
| CATX | CLUSTER | neutral | 2/10 | Two 10% owner entities (Lantheus Holdings, Inc. and Lantheus Alpha Therapy, LLC) sold a combined ~$243K in open-market t | Sep 5, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP/General Counsel Paul Mahon sold a combined $1.23M in open-market shares on September 3, 20 | Sep 5, 2026 |
| KRYS | CLUSTER | bearish | 5/10 | Two top executives at Krystal Biotech (CEO Krish S. Krishnan and President of R&D Suma Krishnan) sold a combined ~$12.8M | Sep 4, 2026 |
| NVS | 6-K | bearish | 6/10 | Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen, an investigational antisense oligonucleotide ta | Sep 4, 2026 |